Real-World data reveals how combo therapy fares against Tough-to-Treat lymphoma
NCT ID NCT07145125
Summary
This study looked back at the real-world results of a two-drug combination (brentuximab vedotin and bendamustine) for patients whose Hodgkin lymphoma returned or did not respond to initial treatment. It included 222 adult patients in France to see how well the treatment worked and what side effects occurred. The goal was to provide clearer information to help guide treatment decisions for this challenging situation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH de la Côte Basque, service Hématologie Clinique
Bayonne, France
-
CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire
Bordeaux, France
-
CHU de Caen, service Hématologie Clinique
Caen, France
-
CHU de Toulouse, service Hématologie Clinique
Toulouse, France
-
Institut Paoli Calmettes, service Hématologie Clinique
Marseille, France
Conditions
Explore the condition pages connected to this study.